Literature DB >> 19720384

Essential tremor as a neuropsychiatric disorder.

Elan D Louis1.   

Abstract

The traditional view of essential (ET) tremor is as a mono-symptomatic condition characterized by action tremor. Over the past decade, researchers have learned that this picture is an over-simplification. First, it is clear that many patients also have other motor manifestations (e.g., ataxic gait). Second, the presence of a variety of non-motor features, both cognitive and psychiatric, is now appreciated. Mild cognitive changes (esp. executive dysfunction) have been documented in several studies. More recently, two population-based studies have demonstrated an association between ET and dementia. Clinically, while most of these cases developed Alzheimer's disease, the neuropathological underpinnings of this dementia have not been fully explored. Psychiatric manifestations include specific personality traits, anxiety, social phobia, and depressive symptoms. Depression may be a primary manifestation of the illness rather than a secondary response to disability. The emerging view of ET is that it is a disease whose central feature is action tremor but in which both motor and non-motor features occur. As in other neurodegenerative conditions, ET appears to be more than a disease of the motor system. Further study of these non-motor phenomena will advance our understanding of disease mechanisms and enhance the quality of clinical interactions with patients.

Entities:  

Mesh:

Year:  2009        PMID: 19720384      PMCID: PMC2813410          DOI: 10.1016/j.jns.2009.08.029

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  97 in total

1.  Neurological disorders in Nigerian Africans: a community-based study.

Authors:  B O Osuntokun; A O Adeuja; B S Schoenberg; O Bademosi; V A Nottidge; A O Olumide; O Ige; F Yaria; C L Bolis
Journal:  Acta Neurol Scand       Date:  1987-01       Impact factor: 3.209

2.  Homolateral disappearance of essential tremor after cerebellar stroke.

Authors:  M J Dupuis; P J Delwaide; D Boucquey; R E Gonsette
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

3.  An estimate of the prevalence of dementia in idiopathic Parkinson's disease.

Authors:  R Mayeux; Y Stern; R Rosenstein; K Marder; A Hauser; L Cote; S Fahn
Journal:  Arch Neurol       Date:  1988-03

4.  Locus coeruleus - cerebellum: interaction during development.

Authors:  J Sievers; H P Klemm
Journal:  Bibl Anat       Date:  1982

5.  A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China.

Authors:  S C Li; B S Schoenberg; C C Wang; X M Cheng; D Y Rui; C L Bolis; D G Schoenberg
Journal:  Arch Neurol       Date:  1985-07

6.  Developmental changes in the cerebellar cortex after locus ceruleus lesion with 6-hydroxydopamine in the rat.

Authors:  O Robain; L Lanfumey; J Adrien; E Farkas
Journal:  Exp Neurol       Date:  1985-04       Impact factor: 5.330

7.  Combined resting-postural tremors.

Authors:  W C Koller; F A Rubino
Journal:  Arch Neurol       Date:  1985-07

8.  Prevalence of essential tremor in the Parsi community of Bombay, India.

Authors:  N E Bharucha; E P Bharucha; A E Bharucha; A V Bhise; B S Schoenberg
Journal:  Arch Neurol       Date:  1988-08

9.  Is octopamine a 'false transmitter'? Regional distribution and serial changes in octopamine and noradrenaline following locus coeruleus lesions.

Authors:  T P Hicks; R A Locock; G W Jason
Journal:  Brain Res       Date:  1987-09-22       Impact factor: 3.252

10.  Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals.

Authors:  J M Fritschy; R Grzanna
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

View more
  24 in total

Review 1.  Review on clinical update of essential tremor.

Authors:  Wei Chunling; Xiao Zheng
Journal:  Neurol Sci       Date:  2016-01-09       Impact factor: 3.307

2.  Disorders of balance and gait in essential tremor are associated with midline tremor and age.

Authors:  Martina Hoskovcová; Olga Ulmanová; Otakar Sprdlík; Tomáš Sieger; Jana Nováková; Robert Jech; Evžen Růžička
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

Review 3.  Association between essential tremor and other neurodegenerative diseases: what is the epidemiological evidence?

Authors:  Hiral LaRoia; Elan D Louis
Journal:  Neuroepidemiology       Date:  2011-07-13       Impact factor: 3.282

Review 4.  Essential tremor--a neurodegenerative disorder associated with cognitive defects?

Authors:  Félix Bermejo-Pareja
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

Review 5.  It is time to remove the 'benign' from the essential tremor label.

Authors:  Elan D Louis; Michael S Okun
Journal:  Parkinsonism Relat Disord       Date:  2011-04-12       Impact factor: 4.891

Review 6.  'Essential tremor' or 'the essential tremors': is this one disease or a family of diseases?

Authors:  Elan D Louis
Journal:  Neuroepidemiology       Date:  2013-12-03       Impact factor: 3.282

7.  Audio-vestibular evaluation in patients with essential tremor.

Authors:  Hatice Balaban; Emine Elif Altuntaş; Ismail Onder Uysal; Ilteriş Ahmet Sentürk; Suat Topaktaş
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-29       Impact factor: 2.503

8.  Daytime sleepiness and nighttime sleep quality across the full spectrum of cognitive presentations in essential tremor.

Authors:  Brittany Rohl; Kathleen Collins; Sarah Morgan; Stephanie Cosentino; Edward D Huey; Elan D Louis
Journal:  J Neurol Sci       Date:  2016-10-08       Impact factor: 3.181

9.  A family with Parkinsonism, essential tremor, restless legs syndrome, and depression.

Authors:  A Puschmann; R F Pfeiffer; A J Stoessl; R Kuriakose; J L Lash; J A Searcy; A J Strongosky; C Vilariño-Güell; M J Farrer; O A Ross; D W Dickson; Z K Wszolek
Journal:  Neurology       Date:  2011-05-10       Impact factor: 9.910

Review 10.  What is essential tremor?

Authors:  Rodger J Elble
Journal:  Curr Neurol Neurosci Rep       Date:  2013-06       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.